Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus TOLECTIN 600.
LODINE vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category C
Category C
NSAID
NSAID